NCT04704024View on ClinicalTrials.gov

Reducing Vertical Transmission of Hepatitis B in Africa

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

September 3, 2021

Primary Completion Date

August 1, 2026

Study Completion Date

December 31, 2026

Conditions
Hepatitis B Infection
Interventions
DRUG

Tenofovir Disoproxil Fumarate

oral TDF medication 300 mg daily

DRUG

Lamivudine Oral Solution

Oral lamivudine with weight-based dosing BID from birth until 6 months of age

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of Alabama at Birmingham

OTHER